Clinical Trial Update: Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of BIBF 1120 (nintedanib) in combination with pemetrexed for advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED